Parallel (Randomized) Phase II Evaluation of ARQ 197 and ARQ 197 in Combination With Erlotinib in Papillary Renal Cell Carcinoma

Trial Profile

Parallel (Randomized) Phase II Evaluation of ARQ 197 and ARQ 197 in Combination With Erlotinib in Papillary Renal Cell Carcinoma

Discontinued
Phase of Trial: Phase II

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Tivantinib (Primary) ; Erlotinib
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Sep 2017 Results (n=16) of exome sequencing of tumor samples of patients from this study, presented at the 42nd European Society for Medical Oncology Congress.
    • 10 Jun 2017 Biomarkers information updated
    • 09 May 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Apr 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top